Sign In
Buy ARQT
$21.35
+0.560 (+2.69%)
At Close: Jun 03, 2026
Arcutis Opportunity To Capitalize On Leadership, Pipeline, And Commercial Assets
01:41am, Saturday, 19'th Apr 2025
Arcutis Biotherapeutics is rated a buy with a $19 price target, driven by strong Zoryve sales, a solid balance sheet, and strategic CFO transition. CFO David Topper is stepping down, replaced by Latha
Arcutis to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025
08:00am, Thursday, 17'th Apr 2025
WESTLAKE VILLAGE, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Arcutis Announces Chief Financial Officer Transition
04:30pm, Thursday, 10'th Apr 2025
WESTLAKE VILLAGE, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 04'th Apr 2025
WESTLAKE VILLAGE, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations i
Arcutis Biotherapeutics (ARQT) Moves 10.8% Higher: Will This Strength Last?
11:05am, Thursday, 03'rd Apr 2025
Arcutis Biotherapeutics (ARQT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stren
Arcutis and Padagis Agree to Stay Patent Lawsuit
01:16pm, Wednesday, 02'nd Apr 2025
WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations i
How Much Upside is Left in Arcutis Biotherapeutics (ARQT)? Wall Street Analysts Think 25.85%
10:55am, Friday, 28'th Mar 2025
The consensus price target hints at a 25.9% upside potential for Arcutis Biotherapeutics (ARQT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ea
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
08:00am, Thursday, 27'th Mar 2025
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations i
Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) with prior inadequate response, intolerance, and cont
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average
10:30am, Thursday, 06'th Mar 2025
From a technical perspective, Arcutis Biotherapeutics, Inc. (ARQT) is looking like an interesting pick, as it just reached a key level of support. ARQT recently overtook the 50-day moving average, and
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Wednesday, 05'th Mar 2025
WESTLAKE VILLAGE, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations i
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High?
10:56am, Wednesday, 05'th Mar 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 48.4% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is question
Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting
09:00am, Friday, 28'th Feb 2025
One poster will share pooled INTEGUMENT data of ZORYVE® (roflumilast) cream 0.15% in atopic dermatitis (AD) in patients with prior inadequate response, intolerance, and/or contraindications to topica
Arcutis: ZORYVE Net Product Revenue Growth Isn't The Only Opportunity On Deck
06:17am, Thursday, 27'th Feb 2025
Data from phase 1b study, using ARQ-255 for the treatment of patients with alopecia areata, expected in the 1st half of 2025. The global alopecia areata market size is expected to be worth $6.92 billi
Arcutis Biotherapeutics: Reiterating Strong Buy As Q4 Results Top Expectations
02:28pm, Wednesday, 26'th Feb 2025
Arcutis Biotherapeutics is a strong buy due to ZORYVE's rapid sales growth and potential for positive earnings within 12 months. ZORYVE, a non-steroidal cream for psoriasis and dermatitis, saw Q4 sale
